incyte corp (INCY) Key Developments
ImmunoVaccine Inc. Collaborates with Incyte Corporation to Evaluate Novel Immunotherapy Combination for Patients with Platinum sensitive Ovarian Cancer
Jun 25 15
Immunovaccine Inc. announced that it has entered into a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the combination of Immunovaccine's novel T cell activating immunotherapy, DPX-Survivac, with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Immunovaccine and Incyte will co-fund and conduct a multicenter, open-label Phase 1B study to evaluate the safety, tolerability and efficacy of the novel combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence. The investigational new drug (IND) application for the study, which will test the triple combination of DPX-Survivac, epacadostat and low dose oral cyclophosphamide, is expected to be filed in 2015 in the U.S. and Canada and the study is expected to enroll approximately 20 patients. Results from this study may lead to an expansion of the clinical collaboration to investigate other cancers. DPX-Survivac and epacadostat both target pathways that have been linked to cancer progression, namely survivin and IDO1. High levels of survivin and IDO1 are found in a broad range of cancers, including ovarian cancer, and individually have been shown to correlate with poor patient outcomes. DPX-Survivac is designed to activate T cells of the immune system to recognize survivin-expressing cancer cells. Epacadostat, on the other hand, is designed to inhibit IDO1-mediated immune suppression in the tumor microenvironment. It is therefore hypothesized that co-administration of these immunotherapies may lead to enhanced anti-tumor effects by both activating the immune system to recognize the cancer and simultaneously weakening its defenses.
Incyte Corporation Presents at Piper Jaffray Heartland Summit, Jun-23-2015
Jun 19 15
Incyte Corporation Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: Herve Hoppenot, Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee.
Incyte Corporation Announces Creation of Two New Units; Announces Executive Changes
Jun 19 15
Incyte Corporation announced that it has created two new units to better position the organization for future growth in the U.S. and internationally. One of these is a U.S. country organization that will lead commercial and medical affairs in the United States. In the future, the company expects to establish other similar country- or regionally-based organizations. The other new unit is a Global Product Strategy and Business Development & Licensing (BD&L) unit that will lead global competitive strategies for Incyte’s expanding portfolio beyond Jakafi® (ruxolitinib), as well as review business development opportunities.
Jim Daly, EVP and Chief Commercial Officer, to leave Incyte at end of June, for personal reasons. Barry Flannelly, Pharm. D., has been appointed to the newly created position of Executive Vice President and General Manager U.S., effective immediately. The existing U.S. commercial team, including those responsible for Jakafi, remains intact and will now report into Dr. Flannelly. A newly created position of Head of Global Product Strategy and BD&L is expected to be filled in the near future. During his career, Barry has held positions in medical affairs, strategic planning, commercial operations, including head of sales and head of marketing, and business development.
Eli Lilly and Company and Incyte Corporation Unveils Detailed Data on Two Pivotal Studies of Baricitinib in Rheumatoid Arthritis Eular Congress in Rome
Jun 10 15
Eli Lilly and Company and Incyte Corporation announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in RomeJune 10-13. Lilly and Incyte previously released positive topline results for the RA-BEACON and RA-BUILD studies, both of which met their primary endpoint of ACR20 at twelve weeks as compared to placebo.
Eli Lilly and Company, Incyte Corporation - Special Call
May 28 15
To discuss from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis